𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors

✍ Scribed by A. C. Lockhart; R. Bukowski; M. L. Rothenberg; K. K. Wang; W. Cooper; J. Grover; L. Appleman; P. R. Mayer; M. Shapiro; A. X. Zhu

Publisher
Springer
Year
2006
Tongue
English
Weight
212 KB
Volume
60
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I trial of subcutaneous interleuki
Phase I trial of subcutaneous interleukin-1Ξ± in children with malignant solid tumors
✍ Furman, Wayne L.; Luo, Xiaolong; Fairclough, Diane; Garrison, Leslie; Marina, Ne πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 1 views

Interleukin-1 alpha (IL-1 alpha) is myeloprotective in a variety of animal models of cancer chemotherapy and is similarly beneficial in adults treated with carboplatin, 5-fluorouracil, and after autologous bone marrow transplantation. There are no trials of this agent in children. Our purpose was to

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi